Correction: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis
Oncotarget. 2022 Aug 4:13:968-969.
doi: 10.18632/oncotarget.28104.
eCollection 2022.
1 Program in Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.
2 Department of Experimental Therapeutics, Thoreau Laboratory for Global Health, M2D2, University of Massachusetts, Lowell, MA, USA.
3 Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
4 Department of Immunology and Allergy, The Hospital for Sick Children, Toronto, Ontario, Canada.
5 Laboratory of Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo FG, Italy.
6 Department of Internal Medicine, University of Chicago, Chicago, IL, USA.
7 Q.P.S. Holdings LLC, Pencader Corporate Center, Newark, DE, USA.
8 Institute of Biomedical Engineering, The Edward S. Rogers Sr. Department of Electrical & Computer Engineering, University of Toronto, Toronto, Canada.
9 Department of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Guwahati Biotech Park, Indian Institute of Technology, Guwahati, Assam, India.
10 Department of Immunology and Infectious Diseases, Forsyth Institute, Cambridge, MA, USA.